NCT00990678

Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Hvidovre University Hospital · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets): 1. Calcium 2. Calcium and 25-hydroxy-vitamin D 3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D The endpoints are: * Serum vitamin D * Parathyroid hormone * ionized calcium * T-lymphocyte fractions (naïve, mature, Tregs) * Osteocalcin (bone metabolism)

Conditions

• HIV Seropositive

Interventions

Type	Name	Description
DRUG	Rocaltrol	tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
DRUG	Vitamin D	tablets, vitamin D3, 30 microgram daily
DRUG	Calcium	tablets, 400 mg calcium, 3 times daily

Timeline

• Start date: 2008-04-01
• Primary completion: 2010-02-01
• Completion: 2011-01-01
• First posted: 2009-10-07
• Last updated: 2012-09-17

Locations

1 site across 1 country: Denmark